Related Experiment Video
Updated: Feb 26, 2026
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple
Linda Rolf1, Anne-Hilde Muris2, Amandine Mathias3
1School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands/Academic MS Center Limburg, Zuyderland Medical Center, Sittard, The Netherlands/Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands.
Background:
Epstein-Barr virus (EBV) infection and vitamin D insufficiency are potentially interacting risk factors for multiple sclerosis (MS).
Objectives:
To investigate the effect of high-dose vitamin D3 supplements on antibody levels against the EBV nuclear antigen-1 (EBNA-1) in patients with relapsing-remitting multiple sclerosis (RRMS) and to explore any underlying mechanism affecting anti-EBNA-1 antibody levels.
Methods:
This study utilized blood samples from a randomized controlled trial in RRMS patients receiving either vitamin D3 (14,000 IU/day; n = 30) or placebo ( n = 23) over 48 weeks. Circulating levels of 25-hydroxyvitamin-D, and anti-EBNA-1, anti-EBV viral capsid antigen (VCA), and anti-cytomegalovirus (CMV) antibodies were measured. EBV load in leukocytes, EBV-specific cytotoxic T-cell responses, and anti-EBNA-1 antibody production in vitro were also explored.
Results:
The median antibody levels against EBNA-1, but not VCA and CMV, significantly reduced in the vitamin D3 group (526 (368-1683) to 455 (380-1148) U/mL) compared to the placebo group (432 (351-1280) to 429 (297-1290) U/mL; p = 0.023). EBV load and cytotoxic T-cell responses were unaffected. Anti-EBNA-1 antibody levels remained below detection limits in B-cell cultures.
Conclusion:
High-dose vitamin D3 supplementation selectively reduces anti-EBNA-1 antibody levels in RRMS patients. Our exploratory studies do not implicate a promoted immune response against EBV as the underlying mechanism.
Insights
High-dose vitamin D3 supplements significantly reduced Epstein-Barr virus nuclear antigen-1 (EBNA-1) antibody levels in multiple sclerosis (MS) patients. This suggests a potential therapeutic avenue, though the exact immune mechanism remains unclear.
Area of Science:
- Neurology
- Immunology
- Nutritional Science
Background:
- Epstein-Barr virus (EBV) infection and vitamin D insufficiency are potential interacting risk factors for multiple sclerosis (MS).
- Understanding the interplay between EBV and vitamin D in MS pathogenesis is crucial.
Purpose of the Study:
- To investigate the effect of high-dose vitamin D3 supplementation on antibody levels against EBV nuclear antigen-1 (anti-EBNA-1) in relapsing-remitting MS (RRMS) patients.
- To explore potential underlying mechanisms influencing anti-EBNA-1 antibody levels.
Main Methods:
- A randomized controlled trial involving RRMS patients receiving high-dose vitamin D3 (14,000 IU/day) or placebo for 48 weeks.
- Measurement of 25-hydroxyvitamin D, anti-EBNA-1, anti-EBV viral capsid antigen (VCA), and anti-cytomegalovirus (CMV) antibodies.
- Exploration of EBV load, cytotoxic T-cell responses, and in vitro anti-EBNA-1 antibody production.
Main Results:
- Vitamin D3 supplementation significantly reduced median anti-EBNA-1 antibody levels compared to placebo (p=0.023).
- No significant effect was observed on anti-VCA, anti-CMV antibody levels, EBV load, or cytotoxic T-cell responses.
- Anti-EBNA-1 antibody levels remained undetectable in B-cell cultures.
Conclusions:
- High-dose vitamin D3 supplementation selectively lowers anti-EBNA-1 antibody levels in RRMS patients.
- The study did not identify a promoted immune response against EBV as the mechanism behind this reduction.
